10/552607 JC09 Rec'd PCT/PTO 05 OCT 2005.

PATENT ATTORNEY DOCKET NO. 056646-5030-US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HODGINS, Malcolm, Briden et al.

National Stage of PCT/GB 2004/001495

Group Art Unit: not yet assigned

Filed: Concurrently

Examiner: not yet assigned

For:

MURINE LIVING TISSUE MODEL & USES

**THEREOF** 

MAIL STOP PCT Alexandria, VA 22313-1450

Sir:

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

A copy of each listed document is attached. An International Search Report citing these documents and setting forth the relevance thereof is also enclosed for the Examiner's consideration. Applicant respectfully requests that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

10/552607

## JC09 Rec'd PCT/PTO 0 5 OCT 2005,

ATTORNEY DOCKET NO.: 056646-5030-US Page 2

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Michael S. Tuscan Reg. No. 43,210

Dated: October 5, 2005 MORGAN, LEWIS & BOCKIUS LLP 1111 Pennsylvania Avenue, NW Washington, D.C. 20004 (202) 739-3000

## INFORMATION DISCLOSURE STATEMENT

Attorney Docket No. **056646-5030-US** 

Appli 12552607

(Use several sheets if necessary)

Applicants: HODGINS, Malcolm, Briden et al.

Filing Date: concurrently

PTO Form 1449

		1	1	ENT DOCUMENTS	1		<del></del>	_
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing	Date
								-
			FOREIGN PA	ATENT DOCUMENTS				
			_	_		Sub		
		Document Number	Date	Country	Class	Class	Yes	No
	1.	WO 03/018752	03-03-06	U.S.				
		OTHER DOCUME	NTS (Includin	g Author, Title, Date, Pe	ertinent Pages,	Etc.)		
	2.	DELVENNE et al., 2001, The organotypic culture of HPV-transformed keratinocytes: an effective in vitro model for the development of new immunotherapeutic approaches for mucosal (pre)neoplastic lesions, Vaccine Vol. 19, No. 17-19, pgs. 2557-2564.						
	3.	EICHER et al., 1996, Evaluation of Topical Gene Therapy for Head and Neck Squamous Cell Carcinoma in an Organotypic Model, Clinical Cancer Research Vol. 2, No. 10, pgs. 1659-1664.						
	4.	HASSAN et al., 2002, Antitumor Activity of SS(dsFv) PE38 and SS1(dsFv) PE38, Recombinant Antimesothelin Immunotoxins against Human Gynecologic Cancers Grown in Organotypic Culture in Vitr Clinical Cancer Research Vol. 8, No. 11, pgs. 3520-3526.						
	5	MILLER <i>et al.</i> , 1994, <u>Growth Factors in Mouse Mammary Cell Interactions <i>in Vitro</i>, Anticancer Research Vol. 14, No. 5A, pgs. 2033-2038.</u>						
	6.	International Search Report						
Examiner:				Date Considered:				

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation

if not in conformance and not considered. Include copy of this form with next communication to applicant.

1-WA/2166171.1